Regulation or Prohibition? Consumer Choice Center Argues Smart Policy Can Address 7-OH Without Banning

Why it matters

As the FDA pushes for Schedule I classification of 7-OH, a policy analysis argues that prohibition will drive the market underground, similar to failed historical drug prohibition efforts, and that evidence-based regulation with potency limits, labeling, age restrictions, and testing is a more effective path that also preserves research opportunities.

The big picture

The 2016 fight to prevent kratom's emergency scheduling demonstrated that federal agencies cannot ignore science without consequence—a lesson now being tested as 7-OH faces similar scheduling pressure. The FDA recommended Schedule I status for 7-OH in July 2025, but the DEA rulemaking process remains incomplete as of March 2026. The policy brief argues that prohibition fails to address the core problem: unregulated products with unknown potency. It notes that LA County's approach—banning after overdose deaths—came only after failing to impose basic regulatory standards like labeling and potency limits. Los Angeles officials attributed deaths to 7-OH despite lethal amounts of alcohol and other depressants also present, but did not conduct additional toxicological analyses. The analysis draws parallels to alcohol and tobacco regulation, arguing that similar frameworks could work for 7-OH.

Key findings

• Schedule I classification would make 7-OH entirely illegal to buy, sell, or study—foreclosing research that could establish safe use guidelines; criminalizing a naturally occurring kratom alkaloid risks driving entire kratom supply underground; fentanyl remains the primary driver of US overdoses, far eclipsing kratom or 7-OH in scale and lethality; a smarter regulatory path includes potency limits (similar to alcohol proof limits), mandatory labeling, age restrictions (21+), third-party testing for contaminants, safe packaging, and aggressive FDA enforcement against bad actors; prohibition diverts resources from evidence-based interventions like medication-assisted treatment and safe supply models; lack of evidence for nationwide ban should elicit questions, per Frontiers in Pharmacology researchers.

What they say

Deputy Director Yaël Ossowski wrote: "If we want to better regulate and control kratom, 7-OH, plus all the derivatives showing up on shelves, we need to develop clear and effective rules, much like we do with alcohol, tobacco, and even cannabis in states where it is legal. The path of prohibition, currently the only option entertained by state and federal officials, has failed us countless times before."

Bottom line

**Prohibition of 7-OH risks repeating historical policy failures, while evidence-based regulation—potency limits, labeling, testing, age restrictions, enforcement—offers a path that protects consumers without abandoning research or driving users toward deadlier drug supplies.**